​

Boundless Bio (BOLD) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BOLD Stock Rating

Boundless Bio stock's rating consensus is Hold, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (30.00%), 13 Hold (65.00%), 1 Sell (5.00%), and 0 Strong Sell (0.00%).

Hold
Total 20 0 1 13 6 Strong Sell Sell Hold Buy Strong Buy

BOLD Price Target Upside V Benchmarks

TypeNameUpside
StockBoundless Bio-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.12$1.12$1.12
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26--2--2
Feb, 26--2--2
Jan, 26--2--2
Dec, 25--2--2
Nov, 251-2--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.85$-2.60---
Avg Forecast$-6.54$-3.47$-3.74$-5.76$-6.24
High Forecast$-6.46$-3.43$-3.74$-5.76$-6.24
Low Forecast$-6.63$-3.50$-3.74$-5.76$-6.24
Surprise %-41.13%-25.07%---

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-----
Avg Forecast----$8.40M
High Forecast----$8.40M
Low Forecast----$8.40M
Surprise %-----

Net Income Forecast

$-150M $-131M $-112M $-93M $-74M $-55M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.36M$-58.20M---
Avg Forecast$-145.50M$-77.06M$-83.23M$-128.10M$-138.77M
High Forecast$-143.61M$-76.22M$-83.23M$-128.10M$-138.77M
Low Forecast$-147.39M$-77.90M$-83.23M$-128.10M$-138.77M
Surprise %-55.08%-24.48%---

BOLD Forecast FAQ

Is Boundless Bio stock a buy?

Boundless Bio stock has a consensus rating of Hold, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 13 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Boundless Bio is a neutral investment for most analysts.

What is Boundless Bio's price target?

Boundless Bio's price target, set by 20 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.12.

How does Boundless Bio stock forecast compare to its benchmarks?

Boundless Bio's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Boundless Bio over the past three months?

  • March 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Boundless Bio’s EPS forecast?

Boundless Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.74, marking a 43.85% increase from the reported $-2.6 in 2025. Estimates for the following years are $-5.76 in 2027, and $-6.24 in 2028.

What is Boundless Bio’s revenue forecast?

Boundless Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $0, and $8.4M for 2028.

What is Boundless Bio’s net income forecast?

Boundless Bio's net income forecast for the fiscal year ending in December 2026 stands at $-83.231M, representing an 43.02% increase from the reported $-58.197M in 2025. Projections indicate $-128M in 2027, and $-139M in 2028.